• FDA Drug Repurposing Identifies MERS-CoV Inhibitors

  2026-09-08

  de Wilde and colleagues demonstrated that screening an FDA-approved compound library can rapidly identify small molecules that suppress MERS-CoV replication in cell culture. The study positioned Lopinavir (ABT-378) among four repurposing candidates while also showing why cell-based activity requires mechanistic, pharmacokinetic, and in vivo validation before therapeutic conclusions can be drawn.

• Metformin and AMPK in Vocal Fold Fibrosis

  2026-09-08

  A 2025 study reports that metformin reduced collagen accumulation and myofibroblast-associated markers in rabbit vocal fold injury and TGF-β1-stimulated fibroblasts. Its central contribution is linking this antifibrotic effect to AMPK activation, while also identifying important translational limits before clinical application.

• CLEC5A, ISG20, and Causal Atherosclerosis Biology

  2026-09-07

  Zhang et al. integrated GEO transcriptomics, eQTL evidence, Mendelian randomization, and experimental models to investigate causal gene relationships in atherosclerosis. The study identifies CLEC5A and ISG20 as risk-associated genes and provides complementary evidence that ISG20 is elevated in macrophage- and endothelial-rich plaque environments.

• BCA Protein Quantification Kit: K4102 Guide

  2026-09-07

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 supports total-protein measurement in dilute samples, including many detergent-containing biochemical preparations and cell lysates. It is intended for scientific research and sample normalization, not diagnostic, clinical, or medical testing.

• Structural Basis of P/Q-Type Cav2.1 Toxin Sensitivity

  2026-09-05

  The 2024 Cell Research study combines cryo-EM and electrophysiology to explain why P- and Q-type Cav2.1 channels differ in sensitivity to omega-agatoxin IVA. Its structures place the toxin at the extracellular face of voltage-sensing domain IV and connect reduced Q-type inhibition to an alternative NP-containing extracellular loop, providing a framework for selective channel pharmacology.

• Rotenone and the Translational Stress-Response Map

  2026-09-04

  Rotenone is more than a mitochondrial Complex I inhibitor: it is a controllable perturbation for connecting electron-transport failure with ROS, apoptosis, autophagy, and Parkinson’s disease biology. This article outlines how translational researchers can use the compound to build mechanistically aligned models, interpret the circ-Pank1/miR-7a-5p/α-syn pathway, and improve decision-making across cellular and animal studies.

• Firefly Luciferase mRNA: Designing Better Readouts

  2026-09-04

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a bright reporter: it is a tool for separating delivery, translation, and biological effects. This guide presents a readout-first framework for gene expression assays, cell viability studies, and in vivo imaging mRNA workflows.

• CXCR4 Theranostics in Lymphoma: Imaging to Therapy

  2026-09-03

  The reference review presents CXCR4 as a theranostic target that can connect lymphoma imaging, biological stratification, and precision treatment. Its main contribution is an integrated comparison of peptide and small-molecule imaging ligands, radioligand therapies, pharmacologic inhibitors, and antibodies, while highlighting physiological uptake and compensatory CXCR7 signaling as important translational constraints.

• Epalrestat and KEAP1/Nrf2 in Parkinson’s Disease

  2026-09-03

  Jia et al. investigated Epalrestat as a neuroprotective aldose reductase inhibitor in cellular and mouse models of Parkinson’s disease, linking its activity to reduced oxidative stress, improved mitochondrial function, and dopaminergic neuron preservation. The study’s key innovation is evidence that Epalrestat directly interacts with KEAP1 and activates Nrf2 signaling, providing a mechanistic rationale for repurposing research while leaving clinical translation unresolved.

• BCA Protein Assay Kit for Cell Assays

  2026-09-02

  Learn how the BCA Protein Assay Kit (SKU K4101) supports protein concentration measurement in cell viability, proliferation, cytotoxicity, and endothelial injury workflows. This scenario-based guide explains assay principles, sample compatibility, optimization, interpretation, and practical vendor-selection criteria.

• Dabigatran for Thromboembolic Disorders: Evidence Review

  2026-09-02

  The reference review positioned Dabigatran as the first non-vitamin K oral anticoagulant to combine direct inhibition of free and fibrin-bound thrombin with predictable oral pharmacology. Its synthesis found clinically meaningful efficacy across atrial fibrillation, orthopedic venous thromboembolism prevention, and recurrent venous thromboembolism, while emphasizing renal clearance and bleeding management as major determinants of safe use.

• LTI6426 Enhances Panobinostat in Myeloma Models

  2026-09-01

  The reference study shows that the protein disulfide isomerase inhibitor LTI6426 substantially increases panobinostat activity in multiple myeloma models, including a proteasome inhibitor-resistant setting. The combination supports a low-dose panobinostat strategy and identifies ATF3, DDIT3/CHOP, and DNAJB1 as candidate pharmacodynamic biomarkers of endoplasmic reticulum stress.

• Cinoxacin: Mechanism, Spectrum, and Clinical Evidence

  2026-09-01

  The reference study presents Cinoxacin as a DNA synthesis-inhibiting quinolone antibiotic whose main distinguishing features were rapid urinary exposure and activity against important Enterobacteriaceae. Its integrated review of mechanism, antimicrobial spectrum, pharmacokinetics, safety, and clinical efficacy provides a useful framework for urinary tract infection research while also highlighting resistance and susceptibility-testing limitations.

• Eltanexor Workflows for XPO1 Cancer Research

  2026-08-31

  Eltanexor (KPT-8602) connects XPO1 inhibition with nuclear protein retention, apoptosis, and Wnt/β-catenin pathway modulation. This article translates those findings into practical workflows for leukemia, lymphoma, colorectal cancer, and organoid studies, with formulation, assay, and troubleshooting guidance.

• AO/PI Double Staining Kit for Glioma Organoids

  2026-08-31

  The AO/PI Double Staining Kit can serve as more than a rapid cell viability assay: it provides a practical quality-control layer for patient-derived glioma organoids. This article explains how Acridine Orange Propidium Iodide staining complements molecular and immune-context validation without being mistaken for a standalone apoptosis diagnosis.

8428 records 1/562 page Next 12345 下5页 Last page